RDY · Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories has launched its generic Semaglutide Injection in Canada shortly after receiving the Notice of Compliance from Health Canada on April 28, 2026, positioning the company as the pioneer in introducing a generic version of this GLP-1 therapy in the Canadian market and the first G7 nation overall. This rapid market entry underscores Dr. Reddy’s operational readiness and strong regulatory expertise in complex peptide development, enabling quick patient access to an affordable alternative for type 2 diabetes management. The product is formulated as a sterile subcutaneous solution in pre-filled pens offering flexible dosing options—0.25 mg, 0.5 mg from the 2 mg/pen and 1 mg from the 4 mg/pen—at a consistent 1.34 mg/ml concentration, indicated for once-weekly use in adults alongside diet, exercise, and other therapies like metformin or insulin where appropriate, but not for type 1 diabetes or ketoacidosis. CEO Erez Israeli highlighted the company's established presence and market access capabilities in Canada, emphasizing commitment to high-quality, affordable GLP-1 therapies. This launch extends momentum from the recent Obeda® introduction in India, signaling strategic focus on expanding GLP-1 access globally, which could enhance revenue diversification in key therapeutic areas like diabetology amid growing demand for such treatments.